Zacks Investment Research on MSN19h
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease StudyShares of UNITY Biotechnology UBX crashed 28.8% yesterday, following mixed results from a mid-stage non-inferiority study of ...
Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...
This health education program aims to help patients living with COPD experience better health outcomes and improved quality ...
The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can ...
Type I allergy, an IgE antibody triggered hypersensitivity disease, represents a common public health problem affecting about one third of the world´s population. Upon exposure to allergens, IgE ...
The investigators retrospectively evaluated 126 consecutive treatment-naïve nAMD patients (126 eyes) who received a loading ...
In re: Xencor, Inc., Appeal No. 2024-1870 (Fed. Cir. Mar. 13, 2025) ...
Duska noted that the PD-L1 inhibitor pembrolizumab has shown efficacy in the treatment of recurrent or metastatic cervical ...
A subset of patients treated with delgocitinib cream 20 mg/g for moderate to severe chronic hand eczema achieved a ...
Multiple risk factors were associated with denials and longer wait times for biologic treatment in moderate to severe asthma, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback